We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
Read MoreHide Full Article
Merck (MRK - Free Report) announced that it has entered into an exclusive licensing deal with China-based privately-held biotech company LaNova Medicines for the latter’s PD-1xVEGF targeting bispecific antibody candidate, LM-299.
Per the terms of the deal, Merck will acquire the global rights to develop and market LM-299. In return, LaNova will receive an upfront cash payment of $588 million. In addition, Merck will have to pay up to $2.7 billion in milestone payments to LaNova.
The deal is expected to be closed by the end of this year, subject to the fulfillment of customary closing conditions, including regulatory approvals.
LaNova is evaluating LM-299 in an early-stage study in China, which is currently enrolling study participants. Merck intends to advance the clinical development of the drug “with speed and rigor for patients in need.”
MRK Stock Performance
Year to date, Merck’s shares have lost 9.8% compared with the industry’s 7.9% decline.
Image Source: Zacks Investment Research
Therapies Rivaling Merck’s LM-299
Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has been one of the lucrative areas in the treatment of cancer of late. Several smaller biotech companies like Summit Therapeutics (SMMT - Free Report) , Instil Bio (TIL - Free Report) and BioNTech (BNTX - Free Report) are already engaged in developing their respective PD-1/VEGF-targeting antibody candidates, namely ivonescimab, SYN-2510 and BNT327.
Among these, Summit Therapeutics is ahead in terms of clinical development. It recently reported encouraging clinical data from a phase III study that showed that treatment with ivonescimab outperformed Merck’s Keytruda in certain patients with non-small cell lung cancer (NSCLC). Thestudy showed that the SMMT antibody reduced the risk of disease progression or death by nearly half compared with Keytruda.
The above results also make SMMT’s ivonescimab the first drug to achieve a statistically significant improvement compared to MRK’s Keytruda in a head-to-head set-up in a late-stage study in NSCLC indication. Keytruda is also the standard of care in NSCLC indication.
However, the BNTX and TIL candidates are in early or mid-stage development across multiple solid tumors. One of these candidates even carries an edge over ivonescimab. Instil Bio’s SYN-2510 has shown the potential to block both VEGF-A and VEGF-B compared with ivonescimab, which blocks only VEGF-A.
All these deals have one thing in common — all the companies have in-licensed their respective PD-1/VEGF drugs from Chinese biotechs. Summit acquired the exclusive license for ivonescimab from Akeso in 2022 while Instil Bio signed a deal with ImmuneOnco Biopharmaceuticals for SYN-2510 in August. While BioNTech signed a deal for BNT327 with Biotheus last year, BNTX offered to acquire its partner for $800 million this Tuesday.
Our Take
Though the deal seems encouraging, Merck still has a long way to go. The idea behind the LaNova deal is to diversify MRK’s revenue base, which has become highly dependent on Keytruda. In the first nine months of 2024, MRK generated nearly 45% of its total revenues from the drug’s sales. With concerns over Keytruda’s potential loss of exclusivity post-2028, the successful development and potential commercialization of an antibody like LM-299 could help Merck lower its dependence on a single product for growth.
The dual mechanism offered by LM-299 differentiates it from currently available therapies for solid tumors (including Keytruda), as there is a potentially higher expression of both PD-1 and VEGF in tumor tissues compared to the normal tissues in the body.
Image: Bigstock
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
Merck (MRK - Free Report) announced that it has entered into an exclusive licensing deal with China-based privately-held biotech company LaNova Medicines for the latter’s PD-1xVEGF targeting bispecific antibody candidate, LM-299.
Per the terms of the deal, Merck will acquire the global rights to develop and market LM-299. In return, LaNova will receive an upfront cash payment of $588 million. In addition, Merck will have to pay up to $2.7 billion in milestone payments to LaNova.
The deal is expected to be closed by the end of this year, subject to the fulfillment of customary closing conditions, including regulatory approvals.
LaNova is evaluating LM-299 in an early-stage study in China, which is currently enrolling study participants. Merck intends to advance the clinical development of the drug “with speed and rigor for patients in need.”
MRK Stock Performance
Year to date, Merck’s shares have lost 9.8% compared with the industry’s 7.9% decline.
Image Source: Zacks Investment Research
Therapies Rivaling Merck’s LM-299
Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has been one of the lucrative areas in the treatment of cancer of late. Several smaller biotech companies like Summit Therapeutics (SMMT - Free Report) , Instil Bio (TIL - Free Report) and BioNTech (BNTX - Free Report) are already engaged in developing their respective PD-1/VEGF-targeting antibody candidates, namely ivonescimab, SYN-2510 and BNT327.
Among these, Summit Therapeutics is ahead in terms of clinical development. It recently reported encouraging clinical data from a phase III study that showed that treatment with ivonescimab outperformed Merck’s Keytruda in certain patients with non-small cell lung cancer (NSCLC). Thestudy showed that the SMMT antibody reduced the risk of disease progression or death by nearly half compared with Keytruda.
The above results also make SMMT’s ivonescimab the first drug to achieve a statistically significant improvement compared to MRK’s Keytruda in a head-to-head set-up in a late-stage study in NSCLC indication. Keytruda is also the standard of care in NSCLC indication.
However, the BNTX and TIL candidates are in early or mid-stage development across multiple solid tumors. One of these candidates even carries an edge over ivonescimab. Instil Bio’s SYN-2510 has shown the potential to block both VEGF-A and VEGF-B compared with ivonescimab, which blocks only VEGF-A.
All these deals have one thing in common — all the companies have in-licensed their respective PD-1/VEGF drugs from Chinese biotechs. Summit acquired the exclusive license for ivonescimab from Akeso in 2022 while Instil Bio signed a deal with ImmuneOnco Biopharmaceuticals for SYN-2510 in August. While BioNTech signed a deal for BNT327 with Biotheus last year, BNTX offered to acquire its partner for $800 million this Tuesday.
Our Take
Though the deal seems encouraging, Merck still has a long way to go. The idea behind the LaNova deal is to diversify MRK’s revenue base, which has become highly dependent on Keytruda. In the first nine months of 2024, MRK generated nearly 45% of its total revenues from the drug’s sales. With concerns over Keytruda’s potential loss of exclusivity post-2028, the successful development and potential commercialization of an antibody like LM-299 could help Merck lower its dependence on a single product for growth.
The dual mechanism offered by LM-299 differentiates it from currently available therapies for solid tumors (including Keytruda), as there is a potentially higher expression of both PD-1 and VEGF in tumor tissues compared to the normal tissues in the body.
Merck & Co., Inc. Price
Merck & Co., Inc. price | Merck & Co., Inc. Quote
MRK’s Zacks Rank
Merck currently carries a Zacks Rank #3 (Hold).